ZMIZ2

Across TCGA pan-cancer cohorts, ZMIZ2 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated ZMIZ2 data layer compared with 23 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher ZMIZ2 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated ZMIZ2 expression acts as an unfavorable survival marker, although some lineages such as LUAD show a favorable association.

CCRCC, PDAC, and LUAD are the cancer types where ZMIZ2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Median	IV	0.118	0.789	.002	39	view →
PDAC	DFS	Median	III,IV	0.312	0.902	.001	20	view →
LUAD	OS	Tertile	II,III,IV	1.000	0.789	.030	10	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

ZMIZ2–CCRCC (OS)

Open the CCRCC breakdown →